A detailed history of Bridgeway Capital Management, LLC transactions in Biodesix Inc stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 394,311 shares of BDSX stock, worth $339,107. This represents 0.01% of its overall portfolio holdings.

Number of Shares
394,311
Previous 284,511 38.59%
Holding current value
$339,107
Previous $506,000 16.8%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$1.16 - $1.76 $127,367 - $193,248
109,800 Added 38.59%
394,311 $591,000
Q3 2024

Nov 14, 2024

BUY
$1.53 - $1.96 $152,155 - $194,918
99,448 Added 53.74%
284,511 $506,000
Q2 2024

Aug 14, 2024

SELL
$1.21 - $1.71 $53,966 - $76,266
-44,600 Reduced 19.42%
185,063 $283,000
Q1 2024

May 15, 2024

BUY
$1.35 - $2.12 $625 - $981
463 Added 0.2%
229,663 $328,000
Q4 2023

Feb 14, 2024

BUY
$1.2 - $2.13 $59,040 - $104,796
49,200 Added 27.33%
229,200 $421,000
Q3 2023

Nov 14, 2023

SELL
$1.04 - $1.74 $52,000 - $87,000
-50,000 Reduced 21.74%
180,000 $297,000
Q2 2023

Aug 14, 2023

BUY
$1.12 - $1.88 $56,672 - $95,128
50,600 Added 28.21%
230,000 $282,000
Q1 2023

May 15, 2023

BUY
$1.52 - $2.5 $158,688 - $261,000
104,400 Added 139.2%
179,400 $333,000
Q4 2022

Feb 14, 2023

SELL
$0.98 - $2.3 $24,500 - $57,499
-25,000 Reduced 25.0%
75,000 $172,000
Q3 2022

Nov 14, 2022

BUY
$1.24 - $2.89 $62,000 - $144,500
50,000 Added 100.0%
100,000 $127,000
Q2 2022

Aug 15, 2022

SELL
$1.32 - $2.12 $46,200 - $74,200
-35,000 Reduced 41.18%
50,000 $82,000
Q1 2022

May 16, 2022

SELL
$1.69 - $5.81 $33,800 - $116,199
-20,000 Reduced 19.05%
85,000 $144,000
Q4 2021

Feb 14, 2022

BUY
$4.09 - $8.67 $429,450 - $910,350
105,000 New
105,000 $555,000

Others Institutions Holding BDSX

About BIODESIX INC


  • Ticker BDSX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 39,982,000
  • Market Cap $34.4M
  • Description
  • Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...
More about BDSX
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.